Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Prior treatment

• Excisional biopsy or lumpectomy performed prior to randomization
• Surgical axillary staging procedure prior to randomization; pre-neoadjuvant therapy sentinel node biopsy is not permitted
• Definitive clinical or radiologic evidence of metastatic disease; (chest imaging \[mandatory for all patients\] and other imaging \[if required\] must have been performed within 90 days prior to randomization)
• Synchronous or previous contralateral invasive breast cancer; (patients with synchronous and/or previous contralateral ductal carcinoma in situ \[DCIS\] or lobular carcinoma in situ \[LCIS\] are eligible)
• Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS; (patients with synchronous or previous ipsilateral LCIS are eligible)
• Treatment including radiation therapy (RT), chemotherapy, targeted therapy, or endocrine therapy for the currently diagnosed breast cancer prior to randomization
• Previous endocrine therapy such as raloxifene or tamoxifen (or other selective estrogen receptor modulator \[SERM\]) or an aromatase inhibitor for any malignancy
• Previous therapy with anthracycline, taxanes, carboplatin, trastuzumab, or other HER2 targeted therapies for any malignancy
• Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. (these patients are eligible if this therapy is discontinued prior to randomization)
• History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
• Other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-up
• Chronic daily treatment with corticosteroids with a dose of \>= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
• Pregnancy or lactation at the time of study entry; (note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)
• Use of any investigational product within 30 days prior to randomization

Other illness

• FNA alone to diagnose the breast cancer
• Synchronous bilateral invasive breast cancer
• Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:
  • Active cardiac disease:
  • Angina pectoris that requires the use of anti-anginal medication;
  • Ventricular arrhythmias except for benign premature ventricular contractions;
  • Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;
  • Conduction abnormality requiring a pacemaker;
  • Valvular disease with documented compromise in cardiac function; and
  • Symptomatic pericarditis
  • History of cardiac disease:
  • Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function;
  • History of documented congestive heart failure (CHF); and
  • Documented cardiomyopathy
• Uncontrolled hypertension defined as sustained systolic blood pressure (BP) \> 150 mmHg or diastolic BP \> 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)
• Active hepatitis B or hepatitis C with abnormal liver function tests
• Intrinsic lung disease resulting in dyspnea
• Poorly controlled diabetes mellitus
• Active infection or chronic infection requiring chronic suppressive antibiotics
• Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) \>= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
• Malabsorption syndrome, ulcerative colitis, resection of the stomach or small bowel, or other disease significantly affecting gastrointestinal function
• Conditions that would prohibit administration of corticosteroids
• Known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol
• Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements

Lab values

• Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of \< 250 cells/mm\^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking anti-retroviral therapy that may have a potential overlapping toxicity with the study therapy are not eligible

• Patients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer; (comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer)
• Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and estrogen deprivation therapy) and for at least 7 months after the last dose of study therapy
• Submission of tumor samples is required for all patients; the local pathology department policy regarding release of tumor samples must be considered in the screening process; patients whose tumor samples are located in a pathology department that by policy will not submit any samples for research purposes should not be approached for participation in the B-52 trial
• The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
• The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Clinical staging for the primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if clinically node negative; if the regional lymph nodes are cN1 and cytologically or histologically positive or if cN2-N3 with or without a biopsy, the primary breast tumor can be cT0-T4
• The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy
• Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or magnetic resonance imaging \[MRI\]) within 6 weeks prior to randomization; if suspicious or abnormal, fine needle aspirate (FNA) or core biopsy is recommended, also within 6 weeks prior to randomization; findings of these evaluations will be used to determine the nodal status prior to randomization:
  • Nodal status - negative
  • Imaging of the axilla is negative
  • Imaging is suspicious or abnormal but the FNA or core biopsy of the questionable node(s) on imaging is negative
  • Nodal status - positive
  • FNA or core biopsy of the node(s) is cytologically or histologically suspicious or positive
  • Imaging is suspicious or abnormal but FNA or core biopsy was not performed
• Patients may be premenopausal or postmenopausal at the time of randomization; for study purposes, postmenopausal is defined as:
  • Age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or
  • Age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or
  • Documented bilateral oophorectomy
• The tumor must have been determined to be HER2-postive as follows:
  • Immunohistochemistry (IHC) 3+ or
  • In situ hybridization (ISH)-positive (defined by ratio of HER2 to circulating endothelial progenitors \[CEP\]17 \>= 2.0 or HER2 gene copy number \>= 6 per nucleus)
• The tumor must have been determined to be estrogen receptor (ER) and/or progesterone (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guideline recommendations for hormone receptor testing; patients with \>= 1% ER or PgR staining by IHC are considered positive
• Absolute neutrophil count (ANC) must be \>= 1200/mm\^3
• Platelet count must be \>= 100,000/mm\^3
• Hemoglobin must be \>= 10 g/dL
• Total bilirubin must be =\< upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation \> ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin
• Alkaline phosphatase must be =\< 2.5 x ULN for the lab
• Aspartate aminotransferase (AST) must be =\< 1.5 x ULN for the lab
• Alkaline phosphatase and AST may not both be \> the ULN; for example, if the alkaline phosphatase is \> the ULN but =\< 2.5 x ULN, the AST must be =\< the ULN; if the AST is \> the ULN but =\< 1.5 x ULN, the alkaline phosphatase must be =\< ULN; Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =\< 1.5 x ULN; if both were performed, the AST must be =\< 1.5 x ULN
• Patients with AST or alkaline phosphatase \> ULN are eligible for inclusion in the study if liver imaging (computed tomography \[CT\], MRI, positron emission tomography \[PET\]-CT, or PET scan) performed within 6 weeks prior to randomization does not demonstrate metastatic disease and the requirements are met
• Patients with alkaline phosphatase that is \> ULN but =\< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 6 weeks prior to randomization does not demonstrate metastatic disease
• Within 6 weeks prior to randomization, the most recent serum creatinine must be =\< ULN or measured or calculated creatinine clearance must be \> 60 mL/min
• Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional \[2-D\] echocardiogram is preferred; however, multi gated acquisition scan \[MUGA\] scan may be substituted based on institutional preferences); the LVEF must be \>= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is \> 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertain